Developing a management plan for oral anticoagulant reversal

American Journal of Health-System Pharmacy

Volumn 70, Issue 10 SUPPL.1, 2013, Pages

  Dager, William E ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UC San Francisco   (United States)

^d TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; BERIPLEX P N; BLOOD CLOTTING FACTOR 9 COMPLEX; COFACT; DABIGATRAN; ECARIN; FEIBA NF; FRESH FROZEN PLASMA; KANOKAD; PHYTOMENADIONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ECARIN CLOTTING TIME; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; KIDNEY FUNCTION; LABORATORY TEST; LOW DRUG DOSE; MEDICAL DECISION MAKING; PATIENT ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SINGLE DRUG DOSE; THROMBIN TIME; THROMBOEMBOLISM; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 84878344411     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130042     Document Type: Article

References (64)

1. Jansen JO, Thomas R, Loudon MA et al. Damage control resuscitation for patients with major trauma. BMJ. 2009; 338:1436- 40.
2. Hylek EM, Regan S, Go AS et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001; 135:393-400. (Pubitemid 32845864)
3. Gunter OL Jr, Au BK, Isbell JM et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma. 2008; 65:527-34.
4. Holcomb JB, Wade CE, Michalek JE et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008; 248:447-58.
5. Bebulin (factor IX complex) prescribing information. Westlake Village, CA: Baxter Healthcare Corporation; 2011 Apr.www.baxter.com/downloads/healthcare- professionals/products/bebulin-vh-pi.pdf (accessed 2013 Jan 4).
6. Profilnine SD (factor IX complex) prescribing information. Los Angeles, CA: Grifols Biologicals Inc; 2011 Aug. http://www.grifolsusa.com/Controller?-fb= pfch&pAction=-factory&file=profil9-ft.pdf&-fp=0&idPortlet= 15341&idval=385714 (accessed 2013 Jan 4).
7. Preston FE, Laidlaw ST, Sampson B et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Hematol. 2002; 116:619-24. (Pubitemid 34178663)
8. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence- based clinical practice guidelines. Chest.2012; 141(Suppl2):e152S-84S.
9. Keeling D, Baglin T, Tait C et al.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011; 154:311-24.
10. Baker RI, Coughlin PB, Gallus AS et al.; Warfarin Reversal Concensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004; 181:492-7. (Pubitemid 39534470)
11. Baggs JH, Patanwala AE, Williams EM et al. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal. Ann Pharmacother. 2012; 46:51-6.
12. Switzer JA, Rocker J, Mohorn P et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke. 2012; 43:2500-2.
13. Beriplex P/N summary of product characteristics. Marburg, Germany: CSL Behring; 2011 Jul. www.medicines.org.uk/EMC/medicine/21147/SPC/ Beriplex+P+N+250+%26+500+IU/(accessed 2013 Jan 4).
14. Octapharma USA press release. Octapharma USA focuses on urgent surgeries as FDA approves Octaplex for fast track development. Mar 12, 2010. www.octapharma.com/index.php?id=33&L=0&tx-ttnews%5Btt-news%5D= 51&cHash=12e5f6621c0201b7c5d eb95bd5e0b38d (accessed 14 Jan 2013).
15. Clinical trials.gov database. Efficacy and safety study of BERIPLEX® P/N compared with plasma in patients with acute major bleeding caused by anticoagulant therapy. Last updated April 3, 2012. http://clinicaltrials.gov/ ct2/show/NCT00708435 (accessed 2013 Jan 4).
16. Sarode R, Milling TJ, Refaai MA et al. Integrated safety analysis of a 4-factor prothrombin complex concentrate versus plasma in phase III clinical trials. Poster presented at Thrombosis and Hemostasis Summit of North America, Chicago, IL; 2012 May 4. http://cdn.f1000.com/ posters/docs/249931755 (accessed 2013 Jan 4).
17. CSL Behring news release. CSL Behring data shows 4-factor prothrombin complex concentrate is as effective and a more rapid treatment for vitamin K antagonist reversal than current standard of care. May 4, 2012.www.cslbehring. com/s1/cs/enco/1151517263302/news/1255928833642/prdetail.htm (accessed 2013 Jan 4).
18. Lankiewicz MW, Hays J, Friedman KD et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006; 4:967-70.
19. Wójcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarininduced coagulopathy. Int J Emerg Med. 2009; 2:217-25.
20. Pinner NA, Hurdle AC, Oliphant C et al. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg. 2010; 74:631-5.
21. NovoSeven RT (coagulation factor VIIa [recombinant] prescribing information. Princeton, NJ: Novo Nordisk Inc.; 2012 Jan. www.novo-pi.com/ novosevenrt.pdf (accessed 2013 Jan 4).
22. Nishijima DK, Dager WE, Schrot RJ et al. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med. 2010; 17:244-51.
23. Dougherty J, Oyen LJ, Dager WE. Anticoagulation reversal. In: Dager WE, Gulseth MP, Nutescu EA, eds. Anticoagulation therapy: a point-of-care guide. Bethesda, MD: American Society of Health-System Pharmacists; 2011:123-54.
24. Dager WE, King JH, Regalia RC et al. Reversal of elevated international normalized ratios and bleeding with lowdose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006; 26:1091-8. (Pubitemid 44167818)
25. Neel S. Essential warfarin knowledge. In: Gulseth M, ed. Managing anticoagulation patients in the hospital. Bethesda, MD: American Society of Health-System Pharmacists; 2007:133-75.
26. AquaMephyton (phytonadione, aqueous colloidal solution of vitamin K) prescribing information. Whitehouse Station, NJ:Merck & Co., Inc.; 2002 Feb. www.scribd.com/doc/33874512/Merck-Vitamin-K-Package-Insert-Aquamephyton-PI (accessed 2013 Jan 4).
27. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol. 2002; 89:400-6. (Pubitemid 36188012)
28. Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting. Ann Pharmacother. 2012; 46:1617-26.
29. Dager WE. Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects. Ann Pharmacother. 2011; 45:1016-20.
30. Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012; 43:1812-7.
31. Chong CT, Lew TW, Kuperan P et al. Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates. Anaesth Intensive Care. 2010; 38:474-80.
32. Demeyere R, Gillardin S, Arnout J et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010; 99:251-60.
33. Mendelow AD, Gregson BA, Fernandes HM et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005; 365:387-97. (Pubitemid 40179225)
34. Hsia CC, Zurawska JH, Tong MZ et al. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus Med. 2009; 19:43-9.
35. Dentali F, Marchesi C, Pierfranceschi MG et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost. 2011; 106:429-38.
36. Majeed A, Eelde A, Agren A et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res. 2011; 129:146-51.
37. Bobbitt L, Merriman E, Raynes J et al. PROTHROMBINEX(®)-VF (PTX-VF) usage for reversal of coagulopathy: prospective evaluation of thrombogenic risk. Thromb Res. 2011; 128:577-82.
38. Cabral KP, Fraser GL, Duprey J et al. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding. Clin Neurol Neurosurg. [Epub ahead of print] 2012 Jul 24.
39. Rodgers GM. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol. 2012; 87:898-902.
40. Sarode R, Matevosyan K, Bhagat R et al. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg. 2012; 116:491-7.
41. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health-Syst Pharm. 2012; 69:1473-84.
42. Gulati G, Hevelow M, George M et al. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med. 2011; 135:490-4.
43. Benzon HT, Avram MJ, Benzon HA et al. Factor VII levels and international normalized ratios in the early phase of warfarin therapy. Anesthesiology. 2010; 112:298-304.
44. Pradaxa (dabigatran etexilate mesylate) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012 May. www.pradaxa.com/pradaxa-prescribing-information.jsp (accessed 2013 Jan 4).
45. Van Ryn J, Litzenburger T, Waterman A et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol. 2011; 57(Suppl1):E1130. Presented at American College of Cardiology ACC.11 60th Annual Scientific Session & Expo, New Orleans, LA: Apr 5, 2011. http://content.online jacc.org/article.aspx?articleid= 1145540 (accessed 2013 Jan 4).
46. Laulicht B, Bakhru S, Lee C et al. Small molecule antidote for anticoagulants. Circulation. 2012; 126:A11395. Presented at the American Heart Association Scientific Sessions, Los Angeles, CA: Nov 3-7, 2012. http://circ.ahajournals.org/cgi/content/meeting-abstract/126/ 21-MeetingAbstracts/A11395?sid=e9490841-a812-42d8-ab48-2d661cf7fccf (accessed 2013 Jan 4).
47. Viles-Gonzalez JF, Fuster V, Halperin JL. New anticoagulants for prevention of stroke in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011; 22:948-55.
48. Xarel to (rivaroxaban) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2012 Nov.www.xareltohcp.com/sites/default/files/pdf/ xarelto-0.pdf#zoom=100 (accessed 2013 Jan 4).
49. Eliquis (apixaban) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. 2012 Dec. http://packageinserts.bms.com/pi/pi-eliquis.pdf (accessed 2013 Jan 4).
50. Stangier J, Rathgen K, Stähle H et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49:259-68.
51. Dager WE. What are the important drug use errors in dialysis patients? Pharmacokinetic and pharmacodynamic principles. Semin Dial. 2010; 23:466-9.
52. Wanek MR, Horn ET, Elapavaluru S et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012; 46:e21.
53. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013; 61:487-9.
54. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-27.
55. Lindahl TL, Baghaei F, Blixter IF et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011; 105:371-8.
56. Van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR result in patients treated with dabigatran. Am J Med. 2012; 125:417-20.
57. Lindhoff-Last E, Samama MM, Ortel TL et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010; 32:673-9.
58. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573-9.
59. Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108:217-24.
60. Warkentin TE, Margetts P, Connolly SJ et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012; 119: 2172-4.
61. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract. [Epub ahead of print] 2012 Nov 16.
62. Cano E, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012; 10:160-3.
63. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012; 46:e10. [Epub ahead of print] 2012 Apr 10.
64. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. [Epub ahead of print] 2013 Mar 7.